Language

Chinese English

Home page

CPIC 2027 | Agenda Blueprint Released! Planners, Speakers, and Volunteers — Join Us

Sep 28,2026

From CPIC 2026 to CPIC 2027, the CPIC conference is no longer just a conference — it is a continuously evolving global innovation ecosystem.

At CPIC 2026, we proved the convening power of the Eastern home ground with 65 sessions, nearly 1,000 speakers, and 10,000 participants. Today, the complete agenda framework for CPIC 2027 is officially released — full coverage of the global innovative drug industry, fully evolved.

Time Upgrade: Moved up from July to May, positioning itself in the golden window of the global biopharmaceutical calendar.

Scale Upgrade: Dual-hall linkage between 4.2 and 5.2, doubling the conference and exhibition area.

Content Upgrade: 100 conference sessions, 15 parallel sessions every half-day, covering the full spectrum of tracks including regulatory affairs, frontier biotechnologies, AI drug discovery, hot therapeutic areas, manufacturing and supply chain, BD globalization, capitalization, clinical development, and ecosystem building.

Today, the organizers are releasing the conference theme framework and beginning to recruit session planners, speakers, and volunteers. Join

Conference Framework

Opening Ceremony & Keynote Session

Opening Ceremony
CPIC Award
Global Biomedical Technology Frontiers
Dialogue with Leaders of China’s Innovative Pharma Companies
MNC Executive Keynotes
Major Clinical Data Announcements
The Global Race and China’s Strength
AI Transforming Pharma Innovation
Cross-Industry Insights in Pharma

Registration Regulations and Drug Regulation

Global Novel Drug Review & Approval and Registration Compliance
Drug Market Access in Emerging Markets
China’s IIT Regulatory Model
Biosimilar Registration and Regulatory Requirements
Nonclinical Evaluation of Novel Drugs
Human-Machine Collaborative Intelligent Review and Approval System
CMC & GMP Compliance and Inspections for Novel Drug

Frontier Biotechnology Track

Antibody Therapeutics Innovation and Development
ADC Innovation and Development
Small Nucleic Acid Drugs Innovation
Cancer Vaccine Innovation
In Vivo CAR-T Innovation
Stem Cell Therapy Innovation
Immune Cell Therapy Innovation
The Future Path of AAV Innovation
Radiopharmaceutical Innovation and Development
GLP-1/Peptide Therapeutics Innovation
Small Molecule Drug Innovation
Complex Drug Products Development
Molecular Glue and PROTAC
Novel Drug Delivery Systems
Exosome Technology Development and Applications
Live Biotherapeutic Product Development
Organoids and Organs-on-chips
Drug-Device Combination Products Development
Translational Medicine and Companion Diagnostics
Brain-Computer Interface
Embodied AI Robotics

AI for Science (AI4S) and AI Drug Discovery

New Paradigms for Novel Drug R&D in the AI Era
A New Era of Pharma Driven by Digital Intelligence
AI-Driven Drug Discovery and Optimization
AI-Driven Bioprocess Innovation
AI Reshaping the End-to-End Clinical Development Chain
AI-Driven Innovation Practices in Pharma
AI Healthcare

Innovative Development in High-Interest Therapeutic Areas

Oncology and Autoimmune Drug Development
Novel Drug R&D for Metabolic Disorders
CNS Novel Drug R&D Session
Ophthalmology Drug Development
Clinical Development and Commercialization of Rare Disease Therapies
Specialty Drug Innovation and Development Session

Manufacturing and Supply Chain Track

Commercial Manufacturing and CMC
Bioprocess Engineering and Global Industrialization
Cryogenic Bioprocessing
Novel Drug Delivery Technologies
Digital Factory and intelligent Manufacturing
Pharmaceutical Cold Chain Logistics and Radiopharmaceutical Logistics Management

BD and Global Market Partnerships

Embracing a New Era of Pharma BD
Global BD Partnerships for Novel Drugs
Deal-Making Power for Novel Drugs
Cross-Border M&A
Synergistic Development of Local Commercialization and Global Markets
Cross-Border Financing and Innovative Capitalization Pathways for Novel Drugs
China-U.S. Biomedical Collaboration
China-Europe Biomedical Collaboration
China-Japan Biomedical Collaboration
BRICS+ Biomedical Collaboration
China-Korea Biomedical Collaboration
Southeast Asia Biomedical Collaboration
Hong Kong, Macao, and Taiwan Biomedical Collaboration

Capitalization and Commercialization of Novel Drugs

China Healthcare Investment and M&A
Capital Strategy for Biopharma Companies
CFO Forum
Hong Kong IPO and Listing for Biopharma Companies
The Evolution and Beyond of NewCo
Cross-Border Investment Session
Diversified Payment Models for Novel Drugs
Market Access for Novel Drugs

Clinical Development and Real-World Research

Early-Phase Clinical Trials for Novel Drugs
Practical Biostatistics for Novel Drug Development
Data Management
Clinical Operations
Adaptive Clinical Trials
Real-World Data Applications and Innovation
Pharmacovigilance
CTD/eCTD Electronic Submissions and Process Reengineering
Medical Affairs

Building the Novel Drug Ecosystem

Intellectual Property Protection
Innovation and Transformation of Traditional Pharma Companies
Biomedical Park Development
ESG Development in Biopharma
Human Resources Development for Biopharma Companies
PR and IR for Biopharma Companies

Roadshows and Announcements

CPIC Roadshow
Clinical Data Announcements
Major Product/Platform Launches
Blue Book Release
Key Signing Ceremony

Corporate Satellite Meetings

Companies as Host Organizations; Topics and Content Curated by the Companies

One-on-One Meetings

New One-on-One Meeting System Under Development

Organizer Introduction

TONACEA is a top-tier ecosystem platform in China's biopharmaceutical innovation field. With over 20 years of deep cultivation in China's new drug innovation, it has developed into a key platform organization driving China's pharmaceutical innovation forces, and a core hub linking multinational pharmaceutical companies with local innovation. In July 2026, TONACEA brought together global innovative drug ecosystem resources to host THE 1ND CHINA PHARMACEUTICAL INNOVATION CONFERENCE (CPIC 2026).

TONACEA brings together multinational pharmaceutical companies, biotech companies, investment institutions, research institutes, and regulatory experts, building a high-end network and knowledge-sharing system covering the entire R&D value chain. Its business covers industry summits, technology forums, customized corporate training, media communication, and strategic consulting. It has branch offices in Beijing, Shanghai, Suzhou, Guangzhou, Shenzhen, and other cities, forming a nationwide operational network.

TONACEA's WeChat official account and video channel continuously output in-depth industry research, and its views are frequently cited by the capital community and various media, making it a widely recognized "official source" in the industry. The "Huashan Award" jointly released by the platform sets a benchmark for the internationalization of China's innovative drugs and promotes local companies onto the world stage.

Call for Session/Track Planners

The conference is calling for session and roundtable planners/conveners. Session meetings are 2–4 hours, while roundtable discussions last approximately 40 minutes.

Call for Presentations/Roadshows

The conference will be calling for presentations and roadshows. Keynote presentations are 20 minutes, regular presentations are 15 minutes, and roadshows are 8 minutes.

"CPIC Elite Companions Program" Recruitment

The conference is recruiting a number of master's and doctoral students in biomedicine-related fields from home and abroad to participate in the organization and execution of the conference. A good command of spoken English or Japanese is required.